Brief: Prokidney Announces Strategic Updates To Its Phase 3 Program To Accelerate Rilparencel’S Registrational Path To Potential Approval In The U.S.

Prokidney

03/09/2024 13:44

ProKidney Corp  PROK.O :
    * PROKIDNEY ANNOUNCES STRATEGIC UPDATES TO ITS PHASE 3
PROGRAM TO
ACCELERATE RILPARENCEL’S REGISTRATIONAL PATH TO POTENTIAL
APPROVAL IN THE U.S.
    * PROKIDNEY CORP - DISCONTINUED EX-U.S.-BASED PROACT 2 TRIAL
    * PROKIDNEY CORP - FOCUSED COMPANY RESOURCES ON PROACT 1 TO
EXPEDITE ENROLLMENT AND ACCELERATE ESTIMATED TOPLINE DATA
READOUT TO Q3 2027
    * PROKIDNEY CORP - EXPECTS CURRENT CASH TO SUPPORT OPERATING
PLANS
INTO Q1 2027
    * PROKIDNEY CORP - ESTIMATES REVISED PHASE 3 PROGRAM WILL
DELIVER
TOPLINE RESULTS BY Q3 2027 AND REDUCE EXPENSES BY APPROXIMATELY
$150 TO $175 MILLION
    * PROKIDNEY CORP - BELIEVES PHASE 3 REGEN-016 (PROACT 2)
TRIAL IS
NOT REQUIRED FOR INITIAL U.S. REGISTRATION

Source text for Eikon:  ID:nGNX4F64Y8 
Further company coverage:  PROK.O